Reproductive Toxicity Risk Tool Should Be Revised, Schering-Plough Says
Schering-Plough is recommending that FDA's proposed integrative assessment tool for evaluating reproductive toxicity be revised to reduce the number of categories and remove the number scale for assigning patient risk
You may also be interested in...
Seven reproductive toxicity criteria will be considered with equal weight in order to promote consistency and avoid investigator biases in assessing preclinical reproductive toxicity data, members of FDA's reproductive toxicity working group decided.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials